atopic dermatitis

Second Phase 3 trial for Dupixent/Dupilumab: the medicine can significantly reduce itch and skin lesions in patients with uncontrolled prurigo nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit…

2 years ago

Sanofi gains full global rights to a promising antibody for inflammatory disorders with the acquisition of Kymab

(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company…

3 years ago

Almirall’s open innovation platform AlmirallShare announces two new partnerships aimed at finding new ways for the treatment of skin cancer and atopic dermatitis

These collaborations are in response to the calls for innovation via AlmirallShare, the open innovation platform of Almirall and aim…

3 years ago